Fang Bai1, Yunshu Lu1, Kejin Wu2, Qing Chen1, Longlong Ding1, Meixin Ge1, Ziyi Weng3. 1. Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China. 2. Department of Breast Surgery, Gynecology and Obstetrics Hospital of Fudan University, Shanghai, China. 3. Department of General Surgery, Shanghai International Medical Center, Shanghai, China.
Abstract
OBJECTIVE: There is no universal consensus on whether gonadotropin-releasing hormone (GnRH) agonist could protect chemotherapy-induced ovarian damage in premenopausal breast cancer patients. This meta-analysis was conducted to estimate the protective effects of GnRH agonist on premenopausal breast cancer patients in details. METHODS: PubMed, Cochrane Library, Embase, CNKI and the Chinese Wangfang Database, conference proceedings and clinical trials were searched to find studies reported since 2000. Heterogeneity for the eligible data was assessed and a pooled odds ratio (OR) with 95% confidence interval (CI) was calculated. RESULTS: Resumption of menses rate was improved in the GnRH agonist and chemotherapy-combination groups versus chemotherapy-alone groups (OR = 1.36, 95% CI: 1.19-1.56). Furthermore, the results indicated that spontaneous pregnancy rate was improved in the experimental groups versus the controls (OR = 1.90, 95% CI: 1.06-3.41). In addition, no publication bias was found using a Begg's funnel plot. CONCLUSION: The results of the current meta-analysis indicate that a GnRH agonist could improve resumption of menses rate and pregnancy rate for premenopausal breast cancer patients. However, more evaluation may be considered to prove this theory.
OBJECTIVE: There is no universal consensus on whether gonadotropin-releasing hormone (GnRH) agonist could protect chemotherapy-induced ovarian damage in premenopausal breast cancerpatients. This meta-analysis was conducted to estimate the protective effects of GnRH agonist on premenopausal breast cancerpatients in details. METHODS: PubMed, Cochrane Library, Embase, CNKI and the Chinese Wangfang Database, conference proceedings and clinical trials were searched to find studies reported since 2000. Heterogeneity for the eligible data was assessed and a pooled odds ratio (OR) with 95% confidence interval (CI) was calculated. RESULTS: Resumption of menses rate was improved in the GnRH agonist and chemotherapy-combination groups versus chemotherapy-alone groups (OR = 1.36, 95% CI: 1.19-1.56). Furthermore, the results indicated that spontaneous pregnancy rate was improved in the experimental groups versus the controls (OR = 1.90, 95% CI: 1.06-3.41). In addition, no publication bias was found using a Begg's funnel plot. CONCLUSION: The results of the current meta-analysis indicate that a GnRH agonist could improve resumption of menses rate and pregnancy rate for premenopausal breast cancerpatients. However, more evaluation may be considered to prove this theory.
Entities:
Keywords:
GnRH agonist; Meta-analysis; Premenopausal breast cancer; Resumption of menses rate
Authors: Halle C F Moore; Joseph M Unger; Kelly-Anne Phillips; Frances Boyle; Erika Hitre; David Porter; Prudence A Francis; Lori J Goldstein; Henry L Gomez; Carlos S Vallejos; Ann H Partridge; Shaker R Dakhil; Agustin A Garcia; Julie Gralow; Janine M Lombard; John F Forbes; Silvana Martino; William E Barlow; Carol J Fabian; Lori Minasian; Frank L Meyskens; Richard D Gelber; Gabriel N Hortobagyi; Kathy S Albain Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: Ander Urruticoechea; Monica Arnedos; Geraldine Walsh; Mitch Dowsett; Ian E Smith Journal: Breast Cancer Res Treat Date: 2007-09-13 Impact factor: 4.872
Authors: Eman A Elgindy; Dahlia O El-Haieg; Ola M Khorshid; Eman I Ismail; Mohamed Abdelgawad; Hassan N Sallam; Ahmed M Abou-Setta Journal: Obstet Gynecol Date: 2013-01 Impact factor: 7.661
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Nikita M Shah; Dana M Scott; Pridvi Kandagatla; Molly B Moravek; Erin F Cobain; Monika L Burness; Jacqueline S Jeruss Journal: Ann Surg Oncol Date: 2019-01-24 Impact factor: 5.344